Ameriprise
GALT icon

Ameriprise’s Galectin Therapeutics GALT Stock Holding History

Ameriprise’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-20,199
Closed -$62K – 3747
2020
Q2 		$62K Buy
+20,199
New +$50.8K ﹤0.01% 3610
2014
Q3 		– Sell
-40
Closed -$1K – 5829
2014
Q2 		$1K Buy
+40
New +$498 ﹤0.01% 5340

Other funds holding GALT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
CCB
Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Ameriprise's GALT Position: Q3 2020 in Review

Ameriprise sold out of Galectin Therapeutics (GALT) in Q3 2020, closing a stake of 20,199 shares — an estimated $62K sold.

Ameriprise first reported a position in GALT in Q2 2014 and held it in 2 quarters. The position peaked at $62K in Q2 2020. 71 funds tracked by Wall St. Rank hold GALT as of Q3 2020.

  • Ameriprise reported no remaining Galectin Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Ameriprise sold 20,199 Galectin Therapeutics shares in Q3 2020, an estimated $62K.
  • Ameriprise first reported a position in Galectin Therapeutics in Q2 2014 and held it in 2 quarters.
  • Ameriprise's Galectin Therapeutics position peaked at $62K in Q2 2020.
  • 71 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2020.

Based on Ameriprise's 13F filing for Q3 2020, filed 16 Nov 2020.